Garner brings over two decades of senior finance and investor relations experience to CONMED, including 15 years at C. R. Bard Inc. (Bard), where he most recently served as vice president, Investor Relations. Prior to that, he was vice president, Controller (Division CFO) of Bard’s Medical Division, director of the company’s Corporate Financial Reporting, and controller for the company’s Reynosa Operations. Prior to joining Bard, he served as controller and acting CFO at Echopass Corporation (currently Genesys) and value planning manager at Futura Industries Corporation. Garner earned an MBA from University of Texas – Pan American and a bachelor of science degree in accounting from Brigham Young University. He is also a certified public accountant.
Curt R. Hartman, CONMED’s President and CEO, said, “We are very excited to welcome Todd to CONMED and to our executive team. During his career, he has made significant contributions to building and transforming finance teams, implementing innovative reporting processes, as well as executing large-scale capital allocation and merger and acquisition strategies. Todd’s deep experience and senior leadership skills will be instrumental in continuing to advance our achievement of the company’s growth and profitability goals.”
In November 2017, CONMED announced that Luke A. Pomilio, who served as the company’s executive vice president and CFO for the past three years, had announced his intention to retire. Pomilio will remain with CONMED in the role of advisor to CFO and continue with the company through March 1, 2019, in order to facilitate a smooth transition.
The company has granted an inducement award to Garner consisting of options to purchase 48,000 shares of CONMED common stock that will vest in equal increments over five years.
“CONMED has built an impressive executive team and product portfolio, both of which position the company as an innovative industry leader," Garner said. "I am excited about the strategic milestones the company has achieved to date and am committed to contributing to CONMED reaching its next level of operational and financial success.”
Garner also received 8,000 restricted stock units (RSU) that will vest in equal increments over a four-year period. The stock options and RSUs are subject to the same terms and conditions as CONMED's equity awards to other officers under the company’s Amended and Restated 2015 Long-Term Incentive Plan, and took effect Jan. 2. The stock options have an exercise price equal to the closing price of CONMED's common stock on the NASDAQ Global Select Market on Jan. 2.
CONMED is a medical technology company that provides surgical devices and equipment for minimally invasive procedures. The company’s products are used by surgeons and physicians in a variety of specialties, including orthopedics, general surgery, gynecology, neurosurgery and gastroenterology. CONMED has a direct selling presence in 17 countries, and international sales constitute approximately 50 percent of the company’s total sales. Headquartered in Utica, N.Y., the company employs approximately 3,100 people.